Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 995 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison control condition Clear all

Conditions: Interstitial Lung Disease
Interventions: ILD, Healthy, Pneumonia; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 635 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bipolar Disorder, Bipolar Depression, Manic Depression
Interventions: Uridine, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 13 Years to 21 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Kidney Disease
Interventions: Decision Aid; Other
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pregnancy, Substance Use, Depression, Anxiety
Interventions: Listening to Women and Pregnant and Postpartum People; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 41 Years · Female only
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Crohn Disease
Interventions: Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg); Biological
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 67
States / cities: Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more

Conditions: Psoriasis
Interventions: Placebo for Risankizumab, Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more

Conditions: Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions: Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care; Device · Behavioral · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 15 Years to 40 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control; Drug · Procedure · Other
Lead sponsor: Jeffrey Gelfand; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity, Morbid, Ventilator-Induced Lung Injury, Respiratory Failure
Interventions: Esophageal balloon, Intervention Spontaneous Breathing Trial (SBT) and Extubation, Control Spontaneous Breathing Trial and Extubation, Intervention Weaning after Tracheostomy, Control Weaning after Tracheostomy; Device · Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Greenville, North Carolina

Conditions: PTSD
Interventions: NYX-783, Placebo; Drug
Lead sponsor: Aptinyx; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 37
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Bentonville, Arkansas + 33 more

Conditions: Inflammatory Bowel Diseases
Interventions: Proactive Symptom Monitoring and Care Coordination; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 90 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Olodaterol (BI 1744), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 28
States / cities: Mobile, Alabama • Wheat Ridge, Colorado • Waterbury, Connecticut + 23 more

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: bimekizumab, ustekinumab, placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 7
States / cities: Fountain Valley, California • Los Angeles, California • Northridge, California + 4 more

Conditions: Infertility, Recurrent Pregnancy Loss
Interventions: Next Generation Sequencing after Blastocyst biopsy; Genetic
Lead sponsor: Reprogenetics; Industry
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: GERD
Interventions: Controls & Cases; Other
Lead sponsor: Loren Laine; Other
Eligibility: 21 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: New Haven, Connecticut • West Haven, Connecticut

Conditions: Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions: Pomalidomide 0.5 mg, Placebo, Pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more

Conditions: ADHD
Interventions: PRC-063 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Purdue Pharma, Canada; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more

Conditions: Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
Interventions: Acalabrutinib, Investigator's choice of treatment; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Ocular Hypertension
Interventions: Not listed
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Crohn Disease
Interventions: LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more

Conditions: Obsessive Compulsive Disorder (OCD)
Interventions: Low Intensity Focused Ultrasound; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder (MDD)
Interventions: Extended-Release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more

Conditions: Coronary Artery Disease
Interventions: Prevail DCB, Agent DCB; Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 55
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 48 more

Conditions: Non Insulin Dependent Diabetes, Pregnancy
Interventions: Metformin, Insulin; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)

Uridine Adolescent Bipolar Depression Randomized Controlled Trial

Empowering Patients On Choices for Renal Replacement Therapy (Aim 3) (EPOCH-RRT)

Pilot Randomized Controlled Trial (RCT): Remote SBIRT Vs. In-Person SBIRT

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

EPI-MINN: Targeting Cognition and Motivation - National

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

Providing Optimal PEEP During Mechanical Ventilation for Obese Patients Using Esophageal Balloon

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

Care Coordination and Proactive Care to Improve Utilization of Resources and Reduce Expenditure in High Risk Inflammatory Bowel Disease (IBD) Patients

12 / 48 wk Pivotal PFT vs PBO in COPD II

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis

Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Intraocular Pressure During Robotic Assisted Laparoscopic Procedures Utilizing Steep Trendelenburg Positioning

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

OCD LIFU Target Engagement

Effects of Antidepressants on Sexual Functioning

Prevail Global Study

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes